(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
China bans storing cremated remains in empty 'bone ash apartments'- 5 High Limit Outer Hard Drives For Information Stockpiling
- Triple polar vortex to plunge central and eastern U.S. into Arctic cold through mid-December
- Language Learning Stages: Which One Gets Your Vote?
- Instructions to Choose the Best Web based Advertising Degree Program for Your Objectives
- Peloton recalls more than 800,000 bikes after broken seat posts injure users
- IndiGo lands IATA chief Willie Walsh as new CEO
- Nigeria’s return to Windsor castle signals new era in UK economic partnership
- Saucony's $125 'Comfy, Stylish' Sneakers Are Now $55
